PhaseBio Pharmaceuticals, Inc.
PHAS · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $29,505 | $64,198 | $125,621 | $149,424 |
| - Cash | $7,804 | $18,688 | $41,800 | $56,357 |
| + Debt | $5,372 | $6,844 | $7,845 | $9,784 |
| Enterprise Value | $27,073 | $52,354 | $91,666 | $102,851 |
| Revenue | $208 | $117 | $158 | $335 |
| % Growth | 77.8% | -25.9% | -52.8% | – |
| Gross Profit | $208 | $117 | $158 | $335 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$15,946 | -$10,392 | $86,076 | -$31,572 |
| % Margin | -7,666.3% | -8,882.1% | 54,478.2% | -9,424.5% |
| Net Income | -$16,781 | -$11,289 | $87,830 | -$31,924 |
| % Margin | -8,067.8% | -9,648.7% | 55,588.6% | -9,529.6% |
| EPS Diluted | -0.34 | -0.23 | 1.82 | -0.66 |
| % Growth | -47.8% | -112.6% | 375.8% | – |
| Operating Cash Flow | -$10,411 | -$22,884 | -$19,994 | -$6,132 |
| Capital Expenditures | -$58 | -$49 | -$1,656 | -$638 |
| Free Cash Flow | -$10,469 | -$22,933 | -$21,650 | -$6,770 |